Dapagliflozin fails to show a significant protective effect in COVID-19

Dapagliflozin did not achieve statistical significance for the primary endpoints of prevention of organ dysfunction or recovery when administered to patients with COVID-19 in the DARE-19 trial. However, there were numerically fewer occurrences of organ failure and death with dapagliflozin compared with placebo and numerically fewer adverse events than with the placebo. Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, MO, USA) presented the results of the DARE-19 (NCT04350593) trial [1]. DARE-19 was an international, multicentre, randomised, double-blind, placebo-controlled study of 1,250 patients who were hospitalised with COVID-19. These patients were at high risk for multiple organ failure and death. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is known to have a protective effect in condi...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 July, 202129 July, 2021